Table 1 Baseline clinicopathologic features of the two independent cohorts
Clinicopathologic features | MEDAL cohort n = 195 n (%) | DYNAMIC cohort n = 36 n (%) | P-value |
|---|---|---|---|
Age, years (median, range) | 63 (35–84) | 62.5 (39–78) | 0.67 |
Sex | 0.93 | ||
Female | 82 (42.1%) | 16 (44.4%) | |
Male | 113 (57.9%) | 20 (55.6%) | |
Smoking history | 0.76 | ||
Non-smoker | 116 (59.5%) | 23 (63.9%) | |
Smoker | 79 (40.5%) | 13 (36.1%) | |
Histology | 0.50 | ||
Lung adenocarcinoma | 130 (66.7%) | 28 (77.8%) | |
Lung squamous cell carcinoma | 51 (26.1%) | 7 (19.4%) | |
Other NSCLC | 14 (7.2%) | 1 (2.8%) | |
Pathological stage | 0.28 | ||
I | 128 (65.6%) | 28 (77.8%) | |
II | 37 (19.0%) | 3 (8.3%) | |
≥ IIIA | 30 (15.4%) | 5 (13.9%) | |
Tumor diameter, cm (median, range) | 2.5 (1.0–8.2) | 2.3 (1.1–9.3) | 0.77 |
Visceral pleural involvement | 0.63 | ||
With | 45 (23.1%) | 10 (27.8%) | |
Without | 144 (73.8%) | 24 (66.7%) | |
No data | 6 (3.1%) | 2 (5.5%) | |
Duration of surgical procedure, minutes (median, range) | 140 (60–325) | 132.5 (60–300) | 0.52 |
Surgical method | 1.00 | ||
Lobectomy | 175 (89.7%) | 33 (91.7%) | |
Wedge resection | 20 (10.3%) | 3 (8.3%) | |
Devascularization technique performed during surgery | 0.50 | ||
Arterial first | 134 (68.7%) | 27 (75.0%) | |
Venous first | 49 (25.1%) | 6 (16.7%) | |
No data | 12 (6.2%) | 3 (8.3%) | |
Adjuvant therapy | 0.54 | ||
With | 55 (28.2%) | 8 (22.2%) | |
Chemotherapy | 47 (24.1%) | 7 (19.4%) | |
Targeted therapy | 5 (2.6%) | 1 (2.8%) | |
Immunotherapy | 1 (0.5%) | 0 (0.0%) | |
Radiotherapy | 2 (1.0%) | 0 (0.0%) | |
Without | 140 (71.8%) | 28 (77.8%) | |